Robert E. Reiter, MD, presented “PSMA Imaging as a Biomarker for Early Stage Prostate Cancer” during the 24th Future Directions in Urology Symposium in August 2024 in Colorado Springs, Colorado.
How to cite: Reiter, Robert E. “PSMA Imaging as a Biomarker for Early Stage Prostate Cancer.” August 2024. Accessed Nov 2024. https://grandroundsinurology.com/psma-imaging-as-a-biomarker-for-early-stage-prostate-cancer/
PSMA Imaging as a Biomarker for Early Stage Prostate Cancer – Summary
Robert E. Reiter, MD, discusses PSMA imaging’s potential as a biomarker for early-stage prostate cancer. In this 11-minute presentation, Dr. Reiter compares PSMA PET and MRI. PSMA PET imaging, more sensitive than MRI, can detect cancer presence, tumor size, and potential spread beyond MRI’s capability, offering a possible advantage in early and focal disease management.
PSMA’s prognostic value is explored. Data indicate a correlation between high PSMA uptake (SUV) and higher Gleason scores. Low PSMA expression is linked with more aggressive cancer markers.
Additionally, Dr. Reiter asserts that PSMA’s potential as a guide in surgical procedures, such as radio-guided lymph node removal, could enhance surgical precision and reduce the chance of residual disease.
The Future Directions in Urology Symposium (FDUS) is an annual urology think tank and non-CME educational summit that brings together industry figures and experts to discuss the current state of genitourinary care and define future directions in treatment. Dr. Dreicer delivered this educational activity during the 24th iteration of the meeting in August 2024 in Colorado Springs, Colorado.
ABOUT THE AUTHOR
Robert E. Reiter, MD, MBA, is the Bing Professor of Urology and Molecular Biology and Director of the Prostate Cancer Treatment and Research Program at the David Geffen School of Medicine at the University of California, Los Angeles. He is currently the Principal Investigator of UCLA’s SPORE (Specialized Program in Research Excellence) program, a $12 million research grant from the National Cancer Institute to develop new diagnostic and treatment options for men with prostate cancer. Dr. Reiter’s clinical interests include robotic surgical management of prostate cancer and the use of both MRI and molecular imaging tools to manage this disease. His research is focused on the development of novel antibodies for both treatment and imaging of prostate cancer, as well as on the role of epithelial to mesenchymal transition in castration and treatment resistance. Dr. Reiter completed his undergraduate studies at Yale University and earned his medical degree at Stanford University Medical School.
